Region-specific effects of N,N′-dodecane-1,12-diyl-bis-3-picolinium dibromide on nicotine-induced increase in extracellular dopamine in vivo

Eitemau Tebyg

• The novel nicotinic receptor antagonist N,N′-dodecane-1,12-diyl-bis-3-picolinium dibromide decreases nicotine-induced dopamine metabolism in rat nucleus accumbens
  gan: Rahman, Shafiqur, et al.
  Cyhoeddwyd: (2008)
• PHARMACOKINETICS OF THE NOVEL NICOTINIC RECEPTOR ANTAGONIST, N,N’-DODECANE-1,12-DIYL- bis-3-PICOLINIUM DIBROMIDE (bPiDDB) IN THE RAT
  gan: Albayati, Zaineb A. Fadhel, et al.
  Cyhoeddwyd: (2008)
• The Novel Nicotinic Receptor Antagonist, N,N′-Dodecane-1,12-diyl-bis-3-picolinium Dibromide (bPiDDB), Inhibits Nicotine-evoked [(3)H]Norepinephrine Overflow from Rat Hippocampal Slices
  gan: Smith, Andrew M., et al.
  Cyhoeddwyd: (2009)
• N,N′-Alkane-diyl-bis-3-picoliniums as Nicotinic Receptor Antagonists: Inhibition of Nicotine-induced Dopamine Release and Hyperactivity
  gan: Dwoskin, Linda P., et al.
  Cyhoeddwyd: (2008)
• Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-picolinium)-12-triethylammonium-dodecane dibromide (TMPD)
  gan: Dwoskin, Linda P., et al.
  Cyhoeddwyd: (2007)